Regulator : Early-Stage

Trial Design Stage

Published Date: November 24, 2025

Share to:

Helpful Terms and Definitions

ClinicalTrials.gov Glossary Terms

NIH Glossary of Common Terms

FDA Drug Development and Review Definitions

Resources

Early Stage Regulatory Engagement

Concept Shaping & Strategic Alignment

Early engagement with regulatory bodies sets the foundation for a successful trial by aligning on the fundamental scientific and regulatory assumptions before design choices become fixed. This phase emphasizes dialogue and exploration—allowing sponsors to proactively address uncertainty, introduce innovative approaches, and identify potential regulatory risks while flexibility is highest.

Early engagement typically focuses on:

Overall development strategy and intended indication
Target population and unmet medical need
Acceptability of novel trial designs, endpoints, or technologies
Early safety considerations and monitoring concepts
Regulatory pathway considerations and long-term development planning

Early-Stage Federal Drug Administration (FDA) Meetings

Early engagement with the FDA is foundational to shaping a development program that is both scientifically rigorous and regulatorily sound. During this phase, sponsors can leverage a range of FDA meeting types to introduce the program, explore innovative approaches, and proactively address key areas of uncertainty while design flexibility remains high. These interactions are intended to foster early dialogue, clarify regulatory expectations, and reduce downstream risk by aligning on foundational concepts before detailed protocol development begins.

Scope and Use of This Roadmap

This section provides a high‑level overview of formal FDA meeting pathways and selected regulatory programs commonly used during early‑stage development and concept formation. It does not reflect informal or interim discussions that may occur with FDA review divisions outside of these established mechanisms. This roadmap is written assuming a traditional Phase 1, Phase 2, and Phase 3 drug development pathway; programs pursuing exploratory, decentralized, or alternative development strategies may need to adapt the timing, sequencing, or type of regulatory engagement described here.

Interact Meeting (Initial Targeted Engagement for Regulatory Advice on Products)

Definition

An INTERACT meeting is an early-stage, informal discussion between drug sponsors and the FDA, intended to provide non-binding feedback on a sponsor’s development plan for novel products. These meetings occur prior to filing an IND and focus on key questions related to manufacturing (CMC), toxicology, and early clinical design. Sponsors use this opportunity to clarify strategy, address concerns, and potentially avoid unnecessary studies by receiving targeted advice on innovative products. The issues discussed often relate to IND requirements, including the design of IND-enabling toxicity studies (such as species selection and endpoints), complex manufacturing technologies or processes, development of innovative devices used with drugs or biologics, and the use of cutting-edge testing methodologies.

Purpose

To de-risk and accelerate development by getting early insight into the evidence needed for a future regulatory pathway.

Common Characteristics

Early Stage: Occurs before definitive toxicology studies but after initial product identification and proof-of-concept.
Informal & Non-Binding: Feedback is guidance, not official decisions, and formal meeting minutes aren't issued, though sponsors prepare detailed summaries.
Focused Questions: Sponsors submit concise packages (around 10 pages) with 3-5 specific, tightly worded questions to get targeted input.

Consider Bringing

Cover Letter: State it's an INTERACT request.
Product Intro: Concise description of the product, disease, etc.
Key Questions: 3-5 focused questions with context.
Data Summary: Preclinical, CMC info, and future plans.
Participants: List of attendees from your side.

How it Differes from Pre-IND Meetings:

INTERACT: Earlier, more exploratory, focused on initial strategies, often for novel/complex products.
Pre-IND: More detailed, focuses on data needed for the actual IND submission (e.g., IND-enabling studies).

Pre-IND (Investigational New Drug)

Definition

A Pre-IND meeting is an early-stage, formal interaction between a drug sponsor and the FDA that occurs before submitting an IND application. The meeting is intended to discuss the sponsor’s drug development plan, clarify regulatory expectations, and identify potential issues early. Pre-IND advice may be requested for issues related to the data needed to support the rationale for testing a drug in humans; the design of nonclinical pharmacology, toxicology, and drug activity studies, including the design and potential uses of any proposed treatment studies in animal models; data requirements for an IND application; initial drug development plans; and regulatory requirements for demonstrating safety and efficacy. This meeting provides an opportunity for sponsors to receive FDA feedback on their development strategy, helping to address concerns, refine study designs, and ensure that regulatory requirements are met before advancing to human trials.

Purpose

The meeting is intended to discuss the sponsor’s drug development plan, clarify regulatory expectations, and identify potential issues early.

Common Characteristics

Timing: Typically scheduled after completion of key nonclinical studies but before IND submission.
Format: Formal meeting (teleconference or face-to-face) with FDA review division.
Participants: Sponsor’s development team (clinical, nonclinical, regulatory) and FDA reviewers.
Content: Focused on scientific and regulatory aspects, not marketing.
Outcome: FDA provides written feedback and meeting minutes summarizing recommendations.

Consider Bringing

Meeting Request Letter: Includes objectives, proposed agenda, and questions for FDA.
Briefing Package: Submitted ~30 days before the meeting; should include:
- Drug overview: Mechanism of action, indication.
- Summary of nonclinical data: Pharmacology, toxicology studies.
- CMC information: Manufacturing process, formulation details.
- Clinical development plan: Proposed Phase 1 design.
- Specific questions for FDA: Clear and prioritized.
- Supporting Data: Any available reports, tables, and figures relevant to discussion.
Team Preparedness: Subject matter experts ready to address FDA questions.

Type C Meetings

Definition

A Type C meeting is any meeting other than a Type A, Type B, or Type B (EOP), or Type D meeting regarding the development and review of a product. For example, discussing biomarkers as a new surrogate endpoint.

Purpose

To discuss specific issues that are not urgent (Type A) or milestone-related (Type B). Commonly used for Novel clinical trial designs, Use of biomarkers or surrogate endpoints, Additional data requirements for ongoing development, Clarification on regulatory expectations for unique situations.

Common Characteristics

Flexibility: Can occur at any point during development.
Broader Scope: Covers topics outside standard milestones.
FDA Response Time: Typically scheduled within 75 days of request.
Format: Teleconference, videoconference, or face-to-face.
Outcome: FDA provides written minutes summarizing discussion and recommendations.

Consider Bringing

Meeting Request Letter: Clearly state objectives and rationale for the meeting.
Briefing Package: Submitted at least 30 days before the meeting, including:
- Background information: Drug overview, indication, development history.
- Specific questions for FDA: Well-structured and prioritized.
- Supporting data: Nonclinical, clinical, CMC data relevant to the discussion.
- Proposed agenda: Organized by topic and question.
- Subject Matter Experts: Clinical, nonclinical, regulatory team members prepared to address FDA questions.

Considerations

FDA and industry believe that early consultation between review teams and sponsors is important for development programs where the sponsor intends to use a biomarker as a new surrogate endpoint that has never been previously used as the primary basis for product approval in the proposed context of use.
The FDA expects focused questions and clear objectives for Type C meetings. Avoid overly broad or speculative topics.

Type D Meetings

Definition

A Type D meeting is a relatively new category introduced to allow for focused discussions on a narrow set of issues that do not require the breadth of a Type C meeting. It is intended to provide timely feedback on specific questions without the need for a full-scale meeting.

Purpose

To address a limited number of questions (usually 2 or fewer) that can be answered without extensive review. Common uses are for clarification on a single protocol element, feedback on a specific data analysis approach, discussion of a narrow regulatory question.

Common Characteristics

Scope: Narrow and focused; not for broad development strategy.
FDA Response Time: Typically scheduled within 50 days of request (faster than Type C).
Format: Teleconference or videoconference; usually shorter duration.
Efficiency: Requires less documentation and preparation than Type C.
Outcome: FDA provides written minutes summarizing discussion and recommendations.

Consider Bringing

Meeting Request Letter: Clearly state the specific questions (limited to 2 or fewer) and rationale.
Briefing Package: Submitted at least 30 days before the meeting, including:
- Background information: Only what is necessary to address the questions.
- Supporting data: Focused and concise; avoid unnecessary detail.
- Proposed agenda: Organized around the specific questions.
Subject Matter Experts: Only those relevant to the narrow topic.

Considerations

Type D meetings should be limited to no more than 2 focused topics. If the sponsor has several issues or a complex single issue with multiple questions, a Type C meeting should be requested rather than requesting several Type D meetings. In addition, the issue should not require input from more than 3 disciplines or Divisions.

Resources for Regulatory Engagement

Formal PDUFA Meetings with FDA References

Website

Frequently asked questions on the PIND meeting

End of Phase 1 Meeting References

21 CFR 312.82(b)
21 CFR part 312, subpart E
21 CFR part 314, subpart H or I
21 CFR part 601, subpart E or H

Guidance for Industry

End-of-Phase 2A Meetings

End of Phase 2 Meeting References

Pre-NDA/BLA Meeting Questions References

21 CFR 312.47b(2)

Guidances for Industry

Submitting Meeting Request References

CTTI

Clinical Trials Transformation Initiative

Regulator : Early-Stage

Regulator : Early-Stage

Trial Design Stage

Early Stage Regulatory Engagement

Early-Stage Federal Drug Administration (FDA) Meetings

Scope and Use of This Roadmap

Definition

Purpose

Common Characteristics

Consider Bringing

How it Differes from Pre-IND Meetings:

Definition

Purpose

Common Characteristics

Consider Bringing

Definition

Purpose

Common Characteristics

Consider Bringing

Considerations

Definition

Purpose

Common Characteristics

Consider Bringing

Considerations

Resources for Regulatory Engagement